Blockage of AKAP12 accelerates angiotensin II (Ang II)-induced cardiac injury in mice by regulating the transforming growth factor β1 (TGF-β1) pathway

被引:17
|
作者
Li, Yong [1 ]
Yu, Qiu-Hua [2 ]
Chu, Ying [3 ]
Wu, Wei-Min [2 ]
Song, Jian-Xiang [4 ]
Zhu, Xiao-Bo [2 ]
Wang, Qiang [2 ]
机构
[1] Wujin Peoples Hosp Changzhou, Dept Cardiol, Changzhou 213017, Peoples R China
[2] Wujin Peoples Hosp Changzhou, Dept Cardiothorac, Changzhou 213017, Peoples R China
[3] Wujin Peoples Hosp Changzhou, Cent Lab, Changzhou 213017, Peoples R China
[4] Third Hosp Yancheng, Dept Cardiac Surg, Yancheng 224000, Peoples R China
关键词
AKAP12; Angiotensin II; Cardiac fibrosis; TGF-beta; 1; pathway; RENAL FIBROSIS; TGF-BETA; AUTOPHAGY; PROTEIN; SSECKS/GRAVIN/AKAP12; INFLAMMATION; HYPERTROPHY; DISSECTION; MECHANISMS; COMPLEXES;
D O I
10.1016/j.bbrc.2018.02.200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypertension is a multifactorial chronic inflammatory disease that leads to cardiac remodeling. A-kinase anchor protein 12 (AKAP12) is a scaffolding protein that has multiple functions in various biological events, including the regulation of vessel integrity and differentiation of neural barriers in blood. However, the role of AKAP12 in angiotensin II (Ang II)-induced cardiac injury remains unclear. In the present study, Ang II infusion reduced AKAP12 expressions in the hearts of wild-type (WT) mice, and AKAP12 knockout (KO) enhanced the infiltration of inflammatory cells. In addition, AKAP12 deletion accelerated Ang II-induced cardiac histologic alterations and dysfunction. Further, AKAP12(-/-) aggravated heart failure by promoting the inflammation, oxidative stress, cellular apoptosis, and autophagy induced by Ang II. Furthermore, AKAP12 KO elevated Ang II-induced cardiac fibrosis, as indicated by the following: (1) Masson trichrome staining showed that Ang II infusion markedly increased fibrotic areas of the WT mouse heart, which was greatly accelerated in AKAP12(-/-) mice; (2) immunohistochemistry analysis showed increased expression of transforming growth factor beta 1 (TGF-beta 1) and alpha-smooth muscle actin (alpha-SMA) in the AKAP12(-/-) mouse heart; (3) reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) analysis showed increased expression of fibrosis-related molecules in the AKAP12-deficient mouse heart; and (4) Western blot analysis indicated significantly higher upregulation of p-SMAD2/3 in the AKAP12(-/-) mouse heart. In vitro, AKAP12 knockdown in HL-1 cells was responsible for TGF-beta 1-induced inflammation, the generation of reactive oxygen species (ROS), apoptosis, autophagy, and fibrosis. Furthermore, overexpression of AKAP12 reduced fibrosis triggered by TGF-beta 1 in cells. Overall, our study suggests that fibrosis induced by Ang II may be alleviated by AKAP12 expression through inactivation of the TGF-beta 1 pathway. (C) 2018 Published by Elsevier Inc.
引用
收藏
页码:128 / 135
页数:8
相关论文
共 50 条
  • [1] Platelets Promote Ang II (Angiotensin II)-Induced Atrial Fibrillation by Releasing TGF-β1 (Transforming Growth Factor-β1) and Interacting With Fibroblasts
    Liu, Yang
    Lv, Haichen
    Tan, Ruopeng
    An, Xiangbo
    Niu, Xiao-Hui
    Liu, Yue-Jian
    Yang, Xiaolei
    Yin, Xiaomeng
    Xia, Yun-Long
    [J]. HYPERTENSION, 2020, 76 (06) : 1856 - 1867
  • [2] Enalaprilat-induced cardiac fibroblast proliferation via regulation of transforming growth factor beta 1 (TGF-β1)-expressing anti-angiotensin II (Ang II)
    Yu, Du-Juan
    Xu, Li-Jun
    Yu, Min
    Sun, Hong-Xia
    [J]. AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (25): : 1837 - 1842
  • [3] Thrombospondin-1(TSP-1) mediates stimulations of transforming growth factor-β(TGF-β) bioactivity by glucose and angiotensin II(Ang II) in rat cardiac fibroblasts
    Zhou, Y
    Berecek, KH
    Murphy-Ullrich, JE
    [J]. HYPERTENSION, 2003, 42 (03) : 406 - 406
  • [4] Rhodojaponin II attenuates kidney injury by regulating TGF-β1/Smad pathway in mice with adriamycin nephropathy
    Qiu, Yue
    Zhou, Junfei
    Zhang, Hanqi
    Zhou, Haofeng
    Tang, Hui
    Lei, Chuntao
    Ye, Chen
    You, Chaoqun
    Chen, Yu
    Wang, Yumei
    Xiong, Jing
    Su, Hua
    Yao, Guangmin
    Zhang, Chun
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2019, 243
  • [5] TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II
    Schultz, JEJ
    Witt, SA
    Glascock, BJ
    Nieman, ML
    Reiser, PJ
    Nix, SL
    Kimball, TR
    Doetschman, T
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (06): : 787 - 796
  • [6] Triptolide inhibits angiotensin II induced cardiac fibroblasts proliferation by down-regulating TGF-β1/Smad3 pathway
    Chen, Jian
    Liu, Mao
    Yeh, James
    Tang, Wenyi
    Tan, Guangyi
    Zhou, Zhijuan
    Lin, Xiufang
    Wu, Wei
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (16) : C95 - C95
  • [7] The Role of the Rho/ROCK Pathway in Ang II and TGF-β1-Induced Atrial Remodeling
    Liu, Li-Juan
    Yao, Feng-Juan
    Lu, Gui-Hua
    Xu, Cheng-Gui
    Xu, Zhe
    Tang, Kai
    Cheng, Yun-Jiu
    Gao, Xiu-Ren
    Wu, Su-Hua
    [J]. PLOS ONE, 2016, 11 (09):
  • [8] Exacerbation of Angiotensin II-induced Cardiac Remodeling Through Enhancement of NADPH Oxidase - TGF-β 1 Pathway in Heparin Cofactor II-Deficient Mice
    Sumitomo-Ueda, Yuka
    Aihara, Ken-ichi
    Ise, Takayuki
    Yoshida, Sumiko
    Yagi, Shusuke
    Iwase, Takashi
    Akaike, Masashi
    Sata, Masataka
    Matsumoto, Toshio
    [J]. CIRCULATION, 2009, 120 (18) : S763 - S763
  • [9] Catalpol Alleviates Ang II-Induced Renal Injury Through NF-κB Pathway and TGF-β1/Smads Pathway
    Cong, Cong
    Yuan, Xiaohong
    Hu, Ying
    Chen, Wenjing
    Wang, Yong
    Tao, Lei
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (01) : 116 - 121
  • [10] Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway
    Ding, Jieqiong
    Tang, Qiong
    Luo, Binhua
    Zhang, Lijun
    Lin, Li
    Han, Lu
    Hao, Miaomiao
    Li, Mingyue
    Yu, Liangzhu
    Li, Mincai
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 859